{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,3]],"date-time":"2026-04-03T05:43:10Z","timestamp":1775194990788,"version":"3.50.1"},"reference-count":204,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2018,5,1]],"date-time":"2018-05-01T00:00:00Z","timestamp":1525132800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,5,1]],"date-time":"2018-05-01T00:00:00Z","timestamp":1525132800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2019,5,1]],"date-time":"2019-05-01T00:00:00Z","timestamp":1556668800000},"content-version":"vor","delay-in-days":365,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["jto.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Thoracic Oncology"],"published-print":{"date-parts":[[2018,5]]},"DOI":"10.1016\/j.jtho.2018.02.021","type":"journal-article","created":{"date-parts":[[2018,3,8]],"date-time":"2018-03-08T01:21:48Z","timestamp":1520472108000},"page":"606-623","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":66,"title":["Progress in the Management of Malignant Pleural\u00a0Mesothelioma in 2017"],"prefix":"10.1016","volume":"13","author":[{"given":"Amanda J.","family":"McCambridge","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrea","family":"Napolitano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aaron S.","family":"Mansfield","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dean A.","family":"Fennell","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshitaka","family":"Sekido","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anna K.","family":"Nowak","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thanyanan","family":"Reungwetwattana","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Weimin","family":"Mao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Harvey I.","family":"Pass","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michele","family":"Carbone","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Haining","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tobias","family":"Peikert","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jtho.2018.02.021_bib1","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1002\/jcp.22724","article-title":"Malignant mesothelioma: facts, myths, and hypotheses","volume":"227","author":"Carbone","year":"2012","journal-title":"J\u00a0Cell Physiol"},{"key":"10.1016\/j.jtho.2018.02.021_bib2","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1080\/10937404.2016.1195323","article-title":"Mesothelioma from asbestos exposures: epidemiologic patterns and impact in the United States","volume":"19","author":"Lemen","year":"2016","journal-title":"J\u00a0Toxicol Envir Health B Crit Rev"},{"key":"10.1016\/j.jtho.2018.02.021_bib3","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1002\/ajim.4700030305","article-title":"Occupational exposure to asbestos: population at risk and projected mortality\u20131980-2030","volume":"3","author":"Nicholson","year":"1982","journal-title":"Am J Ind Med"},{"issue":"8","key":"10.1016\/j.jtho.2018.02.021_bib4","doi-asserted-by":"crossref","first-page":"214","DOI":"10.15585\/mmwr.mm6608a3","article-title":"Malignant mesothelioma mortality\u2014United States, 1999-2015","volume":"66","author":"Mazurek","year":"2017","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"10.1016\/j.jtho.2018.02.021_bib5","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1016\/S1470-2045(13)70257-2","article-title":"Asbestos is not just asbestos: an unrecognised health hazard","volume":"14","author":"Baumann","year":"2013","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.jtho.2018.02.021_bib6","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1016\/j.jtho.2016.12.006","article-title":"Improving the accuracy of mesothelioma diagnosis in China","volume":"12","author":"Guo","year":"2017","journal-title":"J\u00a0Thorac Oncol"},{"key":"10.1016\/j.jtho.2018.02.021_bib7","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1001\/jamaoncol.2016.5487","article-title":"Association of asbestos exposure with malignant mesothelioma incidence in Eastern China","volume":"3","author":"Mao","year":"2017","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.jtho.2018.02.021_bib8","doi-asserted-by":"crossref","first-page":"1246","DOI":"10.1016\/j.jtho.2016.04.028","article-title":"Consensus report of the 2015 Weinman International Conference on Mesothelioma","volume":"11","author":"Carbone","year":"2016","journal-title":"J\u00a0Thorac Oncol"},{"key":"10.1016\/j.jtho.2018.02.021_bib9","doi-asserted-by":"crossref","first-page":"4849","DOI":"10.7314\/APJCP.2012.13.10.4849","article-title":"Malignant mesothelioma in Eastern Asia","volume":"13","author":"Bianchi","year":"2012","journal-title":"Asian Pac J Cancer Prev"},{"key":"10.1016\/j.jtho.2018.02.021_bib10","series-title":"R.\u00a0Cancer in Thailand, Vol. 2010-2012","year":"2015"},{"key":"10.1016\/j.jtho.2018.02.021_bib11","doi-asserted-by":"crossref","first-page":"1602534","DOI":"10.1183\/13993003.02534-2016","article-title":"The asbestos fibre burden in human lungs: new insights into the chrysotile debate","volume":"49","author":"Feder","year":"2017","journal-title":"Eur Respir J"},{"key":"10.1016\/j.jtho.2018.02.021_bib12","doi-asserted-by":"crossref","first-page":"1654","DOI":"10.1016\/j.ajpath.2013.07.029","article-title":"Continuous exposure to chrysotile asbestos can cause transformation of human mesothelial cells via HMGB1 and TNF-\u03b1 signaling","volume":"183","author":"Qi","year":"2013","journal-title":"Am J Pathol"},{"key":"10.1016\/j.jtho.2018.02.021_bib13","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1136\/oemed-2016-104133","article-title":"Dose-time-response association between occupational asbestos exposure and pleural mesothelioma","volume":"74","author":"Lacourt","year":"2017","journal-title":"Occup Environ Med"},{"key":"10.1016\/j.jtho.2018.02.021_bib14","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1136\/oemed-2017-104383","article-title":"Non-occupational exposure to asbestos and risk of pleural mesothelioma: review and meta-analysis","volume":"74","author":"Marsh","year":"2017","journal-title":"Occup Environ Med"},{"key":"10.1016\/j.jtho.2018.02.021_bib15","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1136\/oemed-2017-104298","article-title":"Estimation of the global burden of mesothelioma deaths from incomplete national mortality data","volume":"74","author":"Odgerel","year":"2017","journal-title":"Occup Environ Med"},{"key":"10.1016\/j.jtho.2018.02.021_bib16","doi-asserted-by":"crossref","first-page":"259","DOI":"10.21037\/tlcr.2017.05.06","article-title":"Diagnostic and prognostic biomarkers for malignant mesothelioma: an update","volume":"6","author":"Chen","year":"2017","journal-title":"Transl Lung Cancer Res"},{"key":"10.1016\/j.jtho.2018.02.021_bib17","doi-asserted-by":"crossref","first-page":"3087","DOI":"10.1158\/1078-0432.CCR-15-1130","article-title":"HMGB1 and its hyperacetylated isoform are sensitive and specific serum biomarkers to detect asbestos exposure and to identify mesothelioma patients","volume":"22","author":"Napolitano","year":"2016","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.jtho.2018.02.021_bib18","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1080\/09537104.2016.1246712","article-title":"Pretreatment thrombocytosis as a significant prognostic factor in malignant mesothelioma: a meta-analysis","volume":"28","author":"Zhuo","year":"2017","journal-title":"Platelets"},{"key":"10.1016\/j.jtho.2018.02.021_bib19","doi-asserted-by":"crossref","first-page":"57460","DOI":"10.18632\/oncotarget.15404","article-title":"Prognostic significance of neutrophil-to-lymphocyte ratio in patients with malignant pleural mesothelioma: a meta-analysis","volume":"8","author":"Chen","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.jtho.2018.02.021_bib20","doi-asserted-by":"crossref","first-page":"46425","DOI":"10.18632\/oncotarget.17436","article-title":"Prognostic significance of soluble mesothelin in malignant pleural mesothelioma: a meta-analysis","volume":"8","author":"Tian","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.jtho.2018.02.021_bib21","doi-asserted-by":"crossref","first-page":"16456","DOI":"10.1038\/s41598-017-16551-7","article-title":"Circulating complement component 4d (C4d) correlates with tumor volume, chemotherapeutic response and survival in patients with malignant pleural mesothelioma","volume":"7","author":"Klikovits","year":"2017","journal-title":"Sci Rep"},{"key":"10.1016\/j.jtho.2018.02.021_bib22","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1186\/s12885-017-3209-5","article-title":"Midkine is a potential novel marker for malignant mesothelioma with different prognostic and diagnostic values from mesothelin","volume":"17","author":"Ak","year":"2017","journal-title":"BMC Cancer"},{"key":"10.1016\/j.jtho.2018.02.021_bib23","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1186\/s12885-017-3375-5","article-title":"Calretinin as a blood-based biomarker for mesothelioma","volume":"17","author":"Johnen","year":"2017","journal-title":"BMC Cancer"},{"key":"10.1016\/j.jtho.2018.02.021_bib24","doi-asserted-by":"crossref","first-page":"e0176680","DOI":"10.1371\/journal.pone.0176680","article-title":"Plasmatic extracellular vesicle microRNAs in malignant pleural mesothelioma and asbestos-exposed subjects suggest a 2-miRNA signature as potential biomarker of disease","volume":"12","author":"Cavalleri","year":"2017","journal-title":"PLoS One"},{"key":"10.1016\/j.jtho.2018.02.021_bib25","doi-asserted-by":"crossref","first-page":"9280170","DOI":"10.1155\/2017\/9280170","article-title":"Circulating miR-132-3p as a candidate diagnostic biomarker for malignant mesothelioma","volume":"2017","author":"Weber","year":"2017","journal-title":"Dis Markers"},{"key":"10.1016\/j.jtho.2018.02.021_bib26","doi-asserted-by":"crossref","first-page":"3140","DOI":"10.1038\/s41598-017-02694-0","article-title":"Deregulation of miRNAs in malignant pleural mesothelioma is associated with prognosis and suggests an alteration of cell metabolism","volume":"7","author":"De Santi","year":"2017","journal-title":"Sci Rep"},{"key":"10.1016\/j.jtho.2018.02.021_bib27","doi-asserted-by":"crossref","first-page":"32643","DOI":"10.1038\/srep32643","article-title":"Secreted primary human malignant mesothelioma exosome signature reflects oncogenic cargo","volume":"6","author":"Greening","year":"2016","journal-title":"Sci Rep"},{"key":"10.1016\/j.jtho.2018.02.021_bib28","doi-asserted-by":"crossref","first-page":"103","DOI":"10.21873\/cgp.20023","article-title":"A\u00a0proteomic analysis of the malignant mesothelioma secretome using iTRAQ","volume":"14","author":"Creaney","year":"2017","journal-title":"Cancer Genomics Proteomics"},{"key":"10.1016\/j.jtho.2018.02.021_bib29","doi-asserted-by":"crossref","first-page":"2089","DOI":"10.1016\/j.jtho.2016.08.147","article-title":"The IASLC Mesothelioma Staging Project: proposals for revisions of the T descriptors in the forthcoming eighth edition of the TNM classification for pleural mesothelioma","volume":"11","author":"Nowak","year":"2016","journal-title":"J\u00a0Thorac Oncol"},{"key":"10.1016\/j.jtho.2018.02.021_bib30","doi-asserted-by":"crossref","first-page":"2112","DOI":"10.1016\/j.jtho.2016.09.124","article-title":"The IASLC Mesothelioma Staging Project: proposals for the M descriptors and for revision of the TNM stage groupings in the forthcoming (eighth) edition of the TNM classification for mesothelioma","volume":"11","author":"Rusch","year":"2016","journal-title":"J\u00a0Thorac Oncol"},{"key":"10.1016\/j.jtho.2018.02.021_bib31","doi-asserted-by":"crossref","first-page":"2082","DOI":"10.1016\/j.jtho.2016.09.123","article-title":"The IASLC Mesothelioma Staging Project: improving staging of a rare disease through international participation","volume":"11","author":"Pass","year":"2016","journal-title":"J\u00a0Thorac Oncol"},{"key":"10.1016\/j.jtho.2018.02.021_bib32","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1016\/j.lungcan.2014.11.019","article-title":"Radiologic-pathologic correlation of mesothelioma tumor volume","volume":"87","author":"Armato","year":"2015","journal-title":"Lung Cancer"},{"key":"10.1016\/j.jtho.2018.02.021_bib33","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/j.ejrad.2009.02.002","article-title":"Three-dimensional evaluation of chemotherapy response in malignant pleural mesothelioma","volume":"74","author":"Ak","year":"2010","journal-title":"Eur J Radiol"},{"key":"10.1016\/j.jtho.2018.02.021_bib34","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1016\/j.acra.2005.05.021","article-title":"Evaluation of semiautomated measurements of mesothelioma tumor thickness on CT scans","volume":"12","author":"Armato","year":"2005","journal-title":"Acad Radiol"},{"key":"10.1016\/j.jtho.2018.02.021_bib35","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1183\/09031936.00146110","article-title":"Volumetry: an alternative to assess therapy response for malignant pleural mesothelioma?","volume":"38","author":"Frauenfelder","year":"2011","journal-title":"Eur Respir J"},{"key":"10.1016\/j.jtho.2018.02.021_bib36","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1097\/JTO.0b013e3181dd0ef1","article-title":"Assessment of therapy responses and prediction of survival in malignant pleural mesothelioma through computer-aided volumetric measurement on computed tomography scans","volume":"5","author":"Liu","year":"2010","journal-title":"J\u00a0Thorac Oncol"},{"key":"10.1016\/j.jtho.2018.02.021_bib37","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1148\/radiol.2401050727","article-title":"Quantification of lung tumor volume and rotation at 3D dynamic parallel MR imaging with view sharing: preliminary results","volume":"240","author":"Plathow","year":"2006","journal-title":"Radiology"},{"key":"10.1016\/j.jtho.2018.02.021_bib38","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1097\/JTO.0b013e31828354c8","article-title":"Lung volume measurements as a surrogate marker for patient response in malignant pleural mesothelioma","volume":"8","author":"Labby","year":"2013","journal-title":"J\u00a0Thorac Oncol"},{"key":"10.1016\/j.jtho.2018.02.021_bib39","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1160\/ME9050","article-title":"Computer-assisted diagnosis for early stage pleural mesothelioma: towards automated detection and quantitative assessment of pleural thickening from thoracic CT images","volume":"46","author":"Chaisaowong","year":"2007","journal-title":"Methods Inf Med"},{"key":"10.1016\/j.jtho.2018.02.021_bib40","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1118\/1.3525836","article-title":"Computerized segmentation and measurement of malignant pleural mesothelioma","volume":"38","author":"Sensakovic","year":"2011","journal-title":"Med Phys"},{"key":"10.1016\/j.jtho.2018.02.021_bib41","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1093\/annonc\/mds535","article-title":"Disease volumes as a marker for patient response in malignant pleural mesothelioma","volume":"24","author":"Labby","year":"2013","journal-title":"Ann Oncol"},{"key":"10.1016\/j.jtho.2018.02.021_bib42","doi-asserted-by":"crossref","first-page":"241","DOI":"10.21037\/atm.2017.05.23","article-title":"Volumetric assessment in malignant pleural mesothelioma","volume":"5","author":"Murphy","year":"2017","journal-title":"Ann Transl Med"},{"key":"10.1016\/j.jtho.2018.02.021_bib43","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1016\/j.jtho.2016.04.033","article-title":"Identifying the appropriate FISH criteria for defining MET copy number-driven lung adenocarcinoma through oncogene overlap analysis","volume":"11","author":"Noonan","year":"2016","journal-title":"J\u00a0Thorac Oncol"},{"key":"10.1016\/j.jtho.2018.02.021_bib44","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1016\/j.athoracsur.2016.06.069","article-title":"A\u00a0multicenter study of volumetric computed tomography for staging malignant pleural mesothelioma","volume":"102","author":"Rusch","year":"2016","journal-title":"Ann Thorac Surg"},{"key":"10.1016\/j.jtho.2018.02.021_bib45","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.01428-2016","article-title":"Impact of tumour thickness on survival after radical radiation and surgery in malignant pleural mesothelioma","volume":"49","author":"de Perrot","year":"2017","journal-title":"Eur Respir J"},{"key":"10.1016\/j.jtho.2018.02.021_bib46","doi-asserted-by":"crossref","first-page":"e532","DOI":"10.1016\/S1470-2045(17)30459-X","article-title":"Radiotherapy for the treatment of malignant pleural mesothelioma","volume":"18","author":"Perrot","year":"2017","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.jtho.2018.02.021_bib47","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1007\/s11548-016-1511-3","article-title":"Computer-aided volumetric assessment of malignant pleural mesothelioma on CT using a random walk-based method","volume":"12","author":"Chen","year":"2017","journal-title":"Int J Comput Assist Radiol Surg"},{"key":"10.1016\/j.jtho.2018.02.021_bib48","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1038\/modpathol.2016.181","article-title":"MUC4, a novel immunohistochemical marker identified by gene expression profiling, differentiates pleural sarcomatoid mesothelioma from lung sarcomatoid carcinoma","volume":"30","author":"Amatya","year":"2017","journal-title":"Mod Pathol"},{"key":"10.1016\/j.jtho.2018.02.021_bib49","doi-asserted-by":"crossref","first-page":"e1005633","DOI":"10.1371\/journal.pgen.1005633","article-title":"Combined genetic and genealogic studies uncover a large BAP1 cancer syndrome kindred tracing back nine generations to a common ancestor from the 1700s","volume":"11","author":"Carbone","year":"2015","journal-title":"PLoS Genet"},{"key":"10.1016\/j.jtho.2018.02.021_bib50","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1097\/PAS.0000000000000825","article-title":"GATA3 immunohistochemistry for distinguishing sarcomatoid and desmoplastic mesothelioma from sarcomatoid carcinoma of the lung","volume":"41","author":"Berg","year":"2017","journal-title":"Am J Surg Pathol"},{"key":"10.1016\/j.jtho.2018.02.021_bib51","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1097\/PAS.0000000000000852","article-title":"Identification of DAB2 and intelectin-1 as novel positive immunohistochemical markers of epithelioid mesothelioma by transcriptome microarray analysis for its differentiation from pulmonary adenocarcinoma","volume":"41","author":"Kuraoka","year":"2017","journal-title":"Am J Surg Pathol"},{"key":"10.1016\/j.jtho.2018.02.021_bib52","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.lungcan.2016.12.017","article-title":"Immunohistochemical detection of MTAP and BAP1 protein loss for mesothelioma diagnosis: comparison with 9p21 FISH and BAP1 immunohistochemistry","volume":"104","author":"Hida","year":"2017","journal-title":"Lung Cancer"},{"key":"10.1016\/j.jtho.2018.02.021_bib53","doi-asserted-by":"crossref","first-page":"1915","DOI":"10.1016\/j.ejso.2017.05.009","article-title":"Immunohistochemical evaluation of two antibodies against PD-L1 and prognostic significance of PD-L1 expression in epithelioid peritoneal malignant mesothelioma: a RENAPE study","volume":"43","author":"Valmary-Degano","year":"2017","journal-title":"Eur J Surg Oncol"},{"key":"10.1016\/j.jtho.2018.02.021_bib54","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1002\/cncy.21917","article-title":"Determination of PD-L1 expression in effusions from mesothelioma by immuno-cytochemical staining","volume":"125","author":"Mansour","year":"2017","journal-title":"Cancer Cytopathol"},{"key":"10.1016\/j.jtho.2018.02.021_bib55","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1016\/j.jtho.2017.02.013","article-title":"The immune microenvironment, genome-wide copy number aberrations, and survival in mesothelioma","volume":"12","author":"Thapa","year":"2017","journal-title":"J\u00a0Thorac Oncol"},{"key":"10.1016\/j.jtho.2018.02.021_bib56","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.humpath.2017.04.032","article-title":"Expression of ALCAM (CD166) and PD-L1 (CD274) independently predicts shorter survival in malignant pleural mesothelioma","volume":"71","author":"Inaguma","year":"2018","journal-title":"Hum Pathol"},{"key":"10.1016\/j.jtho.2018.02.021_bib57","doi-asserted-by":"crossref","first-page":"e1373235","DOI":"10.1080\/2162402X.2017.1373235","article-title":"The \u201cdon't eat me\u201d signal CD47 is a novel diagnostic biomarker and potential therapeutic target for diffuse malignant mesothelioma","volume":"7","author":"Schurch","year":"2017","journal-title":"Oncoimmunology"},{"key":"10.1016\/j.jtho.2018.02.021_bib58","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1038\/ng.3520","article-title":"Comprehensive genomic analysis of malignant pleural mesothelioma identifies recurrent mutations, gene fusions and splicing alterations","volume":"48","author":"Bueno","year":"2016","journal-title":"Nat Genet"},{"key":"10.1016\/j.jtho.2018.02.021_bib59","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1038\/nrc.2017.42","article-title":"Novel insights into mesothelioma biology and implications for therapy","volume":"17","author":"Yap","year":"2017","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.jtho.2018.02.021_bib60","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1038\/ng.912","article-title":"Germline BAP1 mutations predispose to malignant mesothelioma","volume":"43","author":"Testa","year":"2011","journal-title":"Nat Genet"},{"key":"10.1016\/j.jtho.2018.02.021_bib61","doi-asserted-by":"crossref","first-page":"4388","DOI":"10.1158\/0008-5472.CAN-14-1328","article-title":"Germline mutation of Bap1 accelerates development of asbestos-induced malignant mesothelioma","volume":"74","author":"Xu","year":"2014","journal-title":"Cancer Res"},{"key":"10.1016\/j.jtho.2018.02.021_bib62","doi-asserted-by":"crossref","first-page":"1996","DOI":"10.1038\/onc.2015.243","article-title":"Minimal asbestos exposure in germline BAP1 heterozygous mice is associated with deregulated inflammatory response and increased risk of mesothelioma","volume":"35","author":"Napolitano","year":"2016","journal-title":"Oncogene"},{"key":"10.1016\/j.jtho.2018.02.021_bib63","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1186\/1479-5876-10-179","article-title":"BAP1 cancer syndrome: malignant mesothelioma, uveal and cutaneous melanoma, and MBAITs","volume":"10","author":"Carbone","year":"2012","journal-title":"J\u00a0Transl Med"},{"key":"10.1016\/j.jtho.2018.02.021_bib64","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1001\/jamadermatol.2017.2330","article-title":"Genotypic and phenotypic features of BAP1 cancer syndrome: a report of 8 new families and review of cases in the literature","volume":"153","author":"Haugh","year":"2017","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.jtho.2018.02.021_bib65","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1038\/nrc3459","article-title":"BAP1 and cancer","volume":"13","author":"Carbone","year":"2013","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.jtho.2018.02.021_bib66","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1097\/JTO.0000000000000471","article-title":"High incidence of somatic BAP1 alterations in sporadic malignant mesothelioma","volume":"10","author":"Nasu","year":"2015","journal-title":"J\u00a0Thorac Oncol"},{"key":"10.1016\/j.jtho.2018.02.021_bib67","doi-asserted-by":"crossref","first-page":"13432","DOI":"10.1073\/pnas.1612074113","article-title":"High-density array-CGH with targeted NGS unmask multiple noncontiguous minute deletions on chromosome 3p21 in mesothelioma","volume":"113","author":"Yoshikawa","year":"2016","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.jtho.2018.02.021_bib68","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1038\/modpathol.2016.188","article-title":"Genomic profiling of malignant peritoneal mesothelioma reveals recurrent alterations in epigenetic regulatory genes BAP1, SETD2, and DDX3X","volume":"30","author":"Joseph","year":"2017","journal-title":"Mod Pathol"},{"key":"10.1016\/j.jtho.2018.02.021_bib69","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1016\/j.jtho.2016.12.019","article-title":"BAP1 is altered by copy number loss, mutation, and\/or loss of protein expression in more than 70% of malignant peritoneal mesotheliomas","volume":"12","author":"Leblay","year":"2017","journal-title":"J\u00a0Thorac Oncol"},{"key":"10.1016\/j.jtho.2018.02.021_bib70","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1038\/nature22798","article-title":"BAP1 regulates IP3R3-mediated Ca2+ flux to mitochondria suppressing cell transformation","volume":"546","author":"Bononi","year":"2017","journal-title":"Nature"},{"key":"10.1016\/j.jtho.2018.02.021_bib71","doi-asserted-by":"crossref","first-page":"1694","DOI":"10.1038\/cdd.2017.95","article-title":"Germline BAP1 mutations induce a Warburg effect","volume":"24","author":"Bononi","year":"2017","journal-title":"Cell Death Differ"},{"key":"10.1016\/j.jtho.2018.02.021_bib72","doi-asserted-by":"crossref","first-page":"72513","DOI":"10.18632\/oncotarget.19872","article-title":"Modulating BAP1 expression affects ROS homeostasis, cell motility and\u00a0mitochondrial function","volume":"8","author":"Hebert","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.jtho.2018.02.021_bib73","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1016\/j.jtho.2017.03.023","article-title":"A\u00a0novel BRCA1-associated protein-1 isoform affects response of mesothelioma cells to drugs impairing BRCA1-mediated DNA repair","volume":"12","author":"Parrotta","year":"2017","journal-title":"J\u00a0Thorac Oncol"},{"key":"10.1016\/j.jtho.2018.02.021_bib74","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.canlet.2017.06.028","article-title":"Germline mutations in DNA repair genes predispose asbestos-exposed patients to malignant pleural mesothelioma","volume":"405","author":"Betti","year":"2017","journal-title":"Cancer Lett"},{"key":"10.1016\/j.jtho.2018.02.021_bib75","doi-asserted-by":"crossref","first-page":"74936","DOI":"10.18632\/oncotarget.20465","article-title":"Common, germline genetic variations in the novel tumor suppressor BAP1 and risk of developing different types of cancer","volume":"8","author":"Lin","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.jtho.2018.02.021_bib76","first-page":"3073","article-title":"Puzzling results from BAP1 germline mutations analysis in a group of asbestos-exposed patients in a high-risk area of northeast Italy","volume":"37","author":"Rizzardi","year":"2017","journal-title":"Anticancer Res"},{"key":"10.1016\/j.jtho.2018.02.021_bib77","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1093\/carcin\/bgu227","article-title":"Mesothelioma patients with germline BAP1 mutations have 7-fold improved long-term survival","volume":"36","author":"Baumann","year":"2015","journal-title":"Carcinogenesis"},{"key":"10.1016\/j.jtho.2018.02.021_bib78","doi-asserted-by":"crossref","first-page":"68863","DOI":"10.18632\/oncotarget.20317","article-title":"Diagnostic accuracy of\u00a0BRCA1-associated protein 1 in malignant mesothelioma: a meta-analysis","volume":"8","author":"Wang","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.jtho.2018.02.021_bib79","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1002\/dc.23683","article-title":"Utility of BRCA1-associated protein 1 immunoperoxidase stain to differentiate benign versus malignant mesothelial proliferations in cytologic specimens","volume":"45","author":"McCroskey","year":"2017","journal-title":"Diagn Cytopathol"},{"key":"10.1016\/j.jtho.2018.02.021_bib80","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1111\/his.13123","article-title":"Diagnostic utility of BAP1 and EZH2 expression in malignant mesothelioma","volume":"70","author":"Shinozaki-Ushiku","year":"2017","journal-title":"Histopathology"},{"key":"10.1016\/j.jtho.2018.02.021_bib81","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.humpath.2016.09.026","article-title":"BAP1 immunohistochemistry has limited prognostic utility as a complement of CDKN2A (p16) fluorescence in situ hybridization in malignant pleural mesothelioma","volume":"60","author":"McGregor","year":"2017","journal-title":"Hum Pathol"},{"key":"10.1016\/j.jtho.2018.02.021_bib82","doi-asserted-by":"crossref","first-page":"1675","DOI":"10.1097\/PAS.0000000000000935","article-title":"PAX8 Expression in a subset of malignant peritoneal mesotheliomas and benign mesothelium has diagnostic implications in the differential diagnosis of ovarian serous carcinoma","volume":"41","author":"Chapel","year":"2017","journal-title":"Am J Surg Pathol"},{"key":"10.1016\/j.jtho.2018.02.021_bib83","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1038\/modpathol.2017.108","article-title":"Clinicopathologic and genetic characteristics of young patients with pleural diffuse malignant mesothelioma","volume":"31","author":"Vivero","year":"2017","journal-title":"Mod Pathol"},{"key":"10.1016\/j.jtho.2018.02.021_bib84","doi-asserted-by":"crossref","first-page":"980","DOI":"10.1097\/PAS.0000000000000864","article-title":"A\u00a0subset of malignant mesotheliomas in young adults are associated with recurrent EWSR1\/FUS-ATF1 fusions","volume":"41","author":"Desmeules","year":"2017","journal-title":"Am J Surg Pathol"},{"key":"10.1016\/j.jtho.2018.02.021_bib85","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1001\/jamaoncol.2017.2918","article-title":"Identification of ALK rearrangements in malignant peritoneal mesothelioma","volume":"4","author":"Hung","year":"2018","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.jtho.2018.02.021_bib86","doi-asserted-by":"crossref","first-page":"2636","DOI":"10.1200\/JCO.2003.11.136","article-title":"Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma","volume":"21","author":"Vogelzang","year":"2003","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.jtho.2018.02.021_bib87","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1002\/path.824","article-title":"Vascular endothelial growth factor is an autocrine growth factor in human malignant mesothelioma","volume":"193","author":"Strizzi","year":"2001","journal-title":"J\u00a0Pathol"},{"key":"10.1016\/j.jtho.2018.02.021_bib88","doi-asserted-by":"crossref","first-page":"1591","DOI":"10.1056\/NEJMra050152","article-title":"Advances in malignant mesothelioma","volume":"353","author":"Robinson","year":"2005","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jtho.2018.02.021_bib89","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1002\/ijc.10996","article-title":"Malignant mesothelioma growth inhibition by agents that target the VEGF and VEGF-C autocrine loops","volume":"104","author":"Masood","year":"2003","journal-title":"Int J Cancer"},{"key":"10.1016\/j.jtho.2018.02.021_bib90","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1002\/dc.20767","article-title":"Immunohistochemical expression and distribution of VEGFR-3 in malignant mesothelioma","volume":"35","author":"Filho","year":"2007","journal-title":"Diagn Cytopathol"},{"key":"10.1016\/j.jtho.2018.02.021_bib91","doi-asserted-by":"crossref","first-page":"1405","DOI":"10.1016\/S0140-6736(15)01238-6","article-title":"Bevacizumab for newly diagnosed pleural mesothelioma in the Mesothelioma Avastin Cisplatin Pemetrexed Study (MAPS): a randomised, controlled, open-label, phase 3 trial","volume":"387","author":"Zalcman","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.jtho.2018.02.021_bib92","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.lungcan.2017.05.012","article-title":"Cost-effectiveness analysis of additional bevacizumab to pemetrexed plus cisplatin for malignant pleural mesothelioma based on the MAPS trial","volume":"110","author":"Zhan","year":"2017","journal-title":"Lung Cancer"},{"key":"10.1016\/j.jtho.2018.02.021_bib93","doi-asserted-by":"crossref","first-page":"3591","DOI":"10.1200\/JCO.2017.72.9012","article-title":"Nintedanib plus pemetrexed\/cisplatin in patients with malignant pleural mesothelioma: phase II results from the randomized, placebo-controlled LUME-Meso trial","volume":"35","author":"Grosso","year":"2017","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.jtho.2018.02.021_bib94","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1016\/j.cllc.2017.03.010","article-title":"LUME-Meso: Design and rationale of the phase III part of a placebo-controlled study of nintedanib and pemetrexed\/cisplatin followed by maintenance nintedanib in patients with unresectable malignant pleural mesothelioma","volume":"18","author":"Scagliotti","year":"2017","journal-title":"Clin Lung Cancer"},{"key":"10.1016\/j.jtho.2018.02.021_bib95","doi-asserted-by":"crossref","first-page":"S1746","DOI":"10.1016\/j.jtho.2017.09.328","article-title":"OA 02.01. Randomized phase II study of anetumab ravtansine or vinorelbine in patients with metastatic pleural mesothelioma","volume":"12","author":"Kindler","year":"2017","journal-title":"J\u00a0Thorac Oncol"},{"key":"10.1016\/j.jtho.2018.02.021_bib96","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1001\/jamaoncol.2016.3049","article-title":"Arginine deprivation with pegylated arginine deiminase in patients with argininosuccinate synthetase 1-deficient malignant pleural mesothelioma: a randomized clinical trial","volume":"3","author":"Szlosarek","year":"2017","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.jtho.2018.02.021_bib97","doi-asserted-by":"crossref","first-page":"1778","DOI":"10.1200\/JCO.2016.71.3230","article-title":"Phase 1 dose-escalation study of pegylated arginine deiminase, cisplatin, and pemetrexed in patients with argininosuccinate synthetase 1-deficient thoracic cancers","volume":"35","author":"Beddowes","year":"2017","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.jtho.2018.02.021_bib98","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1038\/nrc3239","article-title":"The blockade of immune checkpoints in cancer immunotherapy","volume":"12","author":"Pardoll","year":"2012","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.jtho.2018.02.021_bib99","doi-asserted-by":"crossref","first-page":"2174","DOI":"10.1093\/annonc\/mdt161","article-title":"Four-year survival rates for patients with metastatic melanoma who received ipilimumab in phase II clinical trials","volume":"24","author":"Wolchok","year":"2013","journal-title":"Ann Oncol"},{"key":"10.1016\/j.jtho.2018.02.021_bib100","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1016\/S1470-2045(13)70381-4","article-title":"Tremelimumab for patients with chemotherapy-resistant advanced malignant mesothelioma: an open-label, single-arm, phase 2 trial","volume":"14","author":"Calabro","year":"2013","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.jtho.2018.02.021_bib101","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1016\/S2213-2600(15)00092-2","article-title":"Efficacy and safety of an intensified schedule of tremelimumab for chemotherapy-resistant malignant mesothelioma: an open-label, single-arm, phase 2 study","volume":"3","author":"Calabro","year":"2015","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.jtho.2018.02.021_bib102","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1016\/S1470-2045(17)30446-1","article-title":"Tremelimumab as second-line or third-line treatment in relapsed malignant mesothelioma (DETERMINE): a multicentre, international, randomised, double-blind, placebo-controlled phase 2b trial","volume":"18","author":"Maio","year":"2017","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.jtho.2018.02.021_bib103","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2016.34.15_suppl.8503","article-title":"Avelumab (MSB0010718C; anti-PD-L1) in patients with advanced unresectable mesothelioma from the JAVELIN solid tumor phase Ib trial: safety, clinical activity, and PD-L1 expression","volume":"34","author":"Hassan","year":"2016","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.jtho.2018.02.021_bib104","doi-asserted-by":"crossref","first-page":"S292","DOI":"10.1016\/j.jtho.2016.11.300","article-title":"OA13.01 A phase II study of nivolumab in malignant pleural mesothelioma (NivoMes): with translational research (TR) biopies","volume":"12","author":"Quispel-Janssen","year":"2017","journal-title":"J\u00a0Thorac Oncol"},{"key":"10.1016\/j.jtho.2018.02.021_bib105","doi-asserted-by":"crossref","first-page":"S1883","DOI":"10.1016\/j.jtho.2017.09.634","article-title":"MA 19.01 A phase II study of nivolumab: a multicenter, open-label, single arm study in malignant pleural mesothelioma (MERIT)","volume":"12","author":"Goto","year":"2017","journal-title":"J\u00a0Thorac Oncol"},{"key":"10.1016\/j.jtho.2018.02.021_bib106","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1016\/S1470-2045(17)30169-9","article-title":"Clinical safety and activity of pembrolizumab in patients with malignant pleural mesothelioma (KEYNOTE-028): preliminary results from a non-randomised, open-label, phase 1b trial","volume":"18","author":"Alley","year":"2017","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.jtho.2018.02.021_bib107","doi-asserted-by":"crossref","first-page":"S293","DOI":"10.1016\/j.jtho.2016.11.301","article-title":"OA13.02. Phase II trial of pembrolizumab in patients with malignant mesothelioma (MM): interim analysis","volume":"12","author":"Kindler","year":"2017","journal-title":"J\u00a0Thorac Oncol"},{"key":"10.1016\/j.jtho.2018.02.021_bib108","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2017.35.18_suppl.LBA8507","article-title":"Second- or third-line nivolumab (Nivo) versus nivo plus ipilimumab (Ipi) in malignant pleural mesothelioma (MPM) patients: results of the IFCT-1501 MAPS2 randomized phase II trial","volume":"35","author":"Scherpereel","year":"2017","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.jtho.2018.02.021_bib109","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2017.35.15_suppl.8558","article-title":"Tremelimumab in combination with durvalumab in first or second-line mesothelioma patients: safety analysis from the phase II NIBIT-MESO-1 study","volume":"35","author":"Calabro","year":"2017","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.jtho.2018.02.021_bib110","doi-asserted-by":"crossref","first-page":"S1746","DOI":"10.1016\/j.jtho.2017.09.329","article-title":"OA 02.02 Ipilimumab and nivolumab in the treatment of recurrent malignant pleural mesothelioma: a phase II study","volume":"12","author":"Disselhorst","year":"2017","journal-title":"J\u00a0Thorac Oncol"},{"key":"10.1016\/j.jtho.2018.02.021_bib111","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1038\/bjc.2017.269","article-title":"Evaluating the effect of immune cells on the outcome of patients with mesothelioma","volume":"117","author":"Chee","year":"2017","journal-title":"Br J Cancer"},{"key":"10.1016\/j.jtho.2018.02.021_bib112","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1111\/ajco.12788","article-title":"PD-L1 expression associated with worse survival outcome in malignant pleural mesothelioma","volume":"14","author":"Nguyen","year":"2018","journal-title":"Asia Pac J Clin Oncol"},{"key":"10.1016\/j.jtho.2018.02.021_bib113","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.1097\/JTO.0000000000000177","article-title":"B7-H1 expression in malignant pleural mesothelioma is associated with sarcomatoid histology and poor prognosis","volume":"9","author":"Mansfield","year":"2014","journal-title":"J\u00a0Thorac Oncol"},{"key":"10.1016\/j.jtho.2018.02.021_bib114","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/j.jtho.2017.09.1968","article-title":"Molecular and histopathological characterization of the tumor immune microenvironment in advanced stage of malignant pleural mesothelioma","volume":"13","author":"Patil","year":"2018","journal-title":"J\u00a0Thorac Oncol"},{"key":"10.1016\/j.jtho.2018.02.021_bib115","doi-asserted-by":"crossref","first-page":"1823","DOI":"10.1056\/NEJMoa1606774","article-title":"Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer","volume":"375","author":"Reck","year":"2016","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jtho.2018.02.021_bib116","doi-asserted-by":"crossref","first-page":"93","DOI":"10.2217\/imt-2017-0121","article-title":"Pembrolizumab as first-line therapy for metastatic non-small-cell lung cancer","volume":"10","author":"Reck","year":"2018","journal-title":"Immunotherapy"},{"key":"10.1016\/j.jtho.2018.02.021_bib117","doi-asserted-by":"crossref","first-page":"1497","DOI":"10.1016\/S1470-2045(16)30498-3","article-title":"Carboplatin and pemetrexed with or without pembrolizumab for advanced, non-squamous non-small-cell lung cancer: a randomised, phase 2 cohort of the open-label KEYNOTE-021 study","volume":"17","author":"Langer","year":"2016","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.jtho.2018.02.021_bib118","doi-asserted-by":"crossref","first-page":"e0121071","DOI":"10.1371\/journal.pone.0121071","article-title":"Analysis of expression of programmed cell death 1 ligand 1 (PD-L1) in malignant pleural mesothelioma (MPM)","volume":"10","author":"Cedr\u00e9s","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.jtho.2018.02.021_bib119","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2017.35.15_suppl.TPS8581","article-title":"Checkmate 743: a phase 3, randomized, open-label trial of nivolumab (nivo) plus ipilimumab (ipi) vs pemetrexed plus cisplatin or carboplatin as first-line therapy in unresectable pleural mesothelioma","volume":"35","author":"Zalcman","year":"2017","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.jtho.2018.02.021_bib120","doi-asserted-by":"crossref","DOI":"10.1016\/j.jtho.2016.11.1518","article-title":"P2.06\u2013025. DREAM\u2014a phase 2 trial of durvalumab with first line chemotherapy in mesothelioma with a safety run in","volume":"12","author":"Nowak","year":"2017","journal-title":"J\u00a0Thorac Oncol"},{"key":"10.1016\/j.jtho.2018.02.021_bib121","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1016\/j.cell.2015.09.001","article-title":"Nuclear FAK controls chemokine transcription, Tregs, and evasion of anti-tumor immunity","volume":"163","author":"Serrels","year":"2015","journal-title":"Cell"},{"key":"10.1016\/j.jtho.2018.02.021_bib122","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1038\/nm.4123","article-title":"Targeting focal adhesion kinase renders pancreatic cancers responsive to checkpoint immunotherapy","volume":"22","author":"Jiang","year":"2016","journal-title":"Nat Med"},{"key":"10.1016\/j.jtho.2018.02.021_bib123","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1038\/nm.3947","article-title":"Loss of BAP1 function leads to EZH2-dependent transformation","volume":"21","author":"LaFave","year":"2015","journal-title":"Nat Med"},{"key":"10.1016\/j.jtho.2018.02.021_bib124","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1073\/pnas.1309085110","article-title":"Tumor suppressor and deubiquitinase BAP1 promotes DNA double-strand break repair","volume":"111","author":"Yu","year":"2014","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.jtho.2018.02.021_bib125","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1158\/2159-8290.CD-15-0583","article-title":"Mesothelin-targeted CARs: driving T Cells to solid tumors","volume":"6","author":"Morello","year":"2016","journal-title":"Cancer Disc"},{"key":"10.1016\/j.jtho.2018.02.021_bib126","doi-asserted-by":"crossref","first-page":"2907","DOI":"10.1158\/0008-5472.CAN-14-0337","article-title":"Discovery of mesothelin and exploiting it as a target for immunotherapy","volume":"74","author":"Pastan","year":"2014","journal-title":"Cancer Res"},{"key":"10.1016\/j.jtho.2018.02.021_bib127","doi-asserted-by":"crossref","first-page":"26744","DOI":"10.18632\/oncotarget.15814","article-title":"Comprehensive immunohistochemical study of mesothelin (MSLN) using different monoclonal antibodies 5B2 and MN-1 in 1562 tumors with evaluation of its prognostic value in malignant pleural mesothelioma","volume":"8","author":"Inaguma","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.jtho.2018.02.021_bib128","doi-asserted-by":"crossref","first-page":"77872","DOI":"10.18632\/oncotarget.20845","article-title":"Cancer antigen profiling for malignant pleural mesothelioma immunotherapy: expression and coexpression of mesothelin, cancer antigen 125, and Wilms tumor 1","volume":"8","author":"Eguchi","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.jtho.2018.02.021_bib129","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1158\/1535-7163.MCT-07-0483","article-title":"Mesothelin is a malignant factor and therapeutic vaccine target for pancreatic cancer","volume":"7","author":"Li","year":"2008","journal-title":"Mol Cancer Ther"},{"key":"10.1016\/j.jtho.2018.02.021_bib130","doi-asserted-by":"crossref","first-page":"4171","DOI":"10.1200\/JCO.2016.68.3672","article-title":"Mesothelin immunotherapy for cancer: ready for prime time?","volume":"34","author":"Hassan","year":"2016","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.jtho.2018.02.021_bib131","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1158\/2326-6066.CIR-16-0330","article-title":"Combining local immunotoxins targeting mesothelin with CTLA-4 blockade synergistically eradicates murine cancer by promoting anticancer immunity","volume":"5","author":"Leshem","year":"2017","journal-title":"Cancer Immunol Res"},{"key":"10.1016\/j.jtho.2018.02.021_bib132","doi-asserted-by":"crossref","first-page":"1564","DOI":"10.1158\/1078-0432.CCR-16-1667","article-title":"Efficacy of anti-mesothelin immunotoxin RG7787 plus Nab-paclitaxel against mesothelioma patient-derived xenografts and mesothelin as a biomarker of tumor response","volume":"23","author":"Zhang","year":"2017","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.jtho.2018.02.021_bib133","doi-asserted-by":"crossref","first-page":"7126","DOI":"10.1158\/1078-0432.CCR-06-1101","article-title":"In\u00a0vivo loss of expression of argininosuccinate synthetase in malignant pleural mesothelioma is a biomarker for susceptibility to arginine depletion","volume":"12","author":"Szlosarek","year":"2006","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.jtho.2018.02.021_bib134","doi-asserted-by":"crossref","first-page":"2861","DOI":"10.1158\/1078-0432.CCR-12-2641","article-title":"ASS1 as a novel tumor suppressor gene in myxofibrosarcomas: aberrant loss via epigenetic DNA methylation confers aggressive phenotypes, negative prognostic impact, and therapeutic relevance","volume":"19","author":"Huang","year":"2013","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.jtho.2018.02.021_bib135","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1038\/nature15529","article-title":"Diversion of aspartate in ASS1-deficient tumours fosters de novo pyrimidine synthesis","volume":"527","author":"Rabinovich","year":"2015","journal-title":"Nature"},{"key":"10.1016\/j.jtho.2018.02.021_bib136","doi-asserted-by":"crossref","first-page":"1815","DOI":"10.1200\/JCO.2004.11.120","article-title":"Pegylated arginine deiminase treatment of patients with unresectable hepatocellular carcinoma: results from phase I\/II studies","volume":"22","author":"Izzo","year":"2004","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.jtho.2018.02.021_bib137","doi-asserted-by":"crossref","first-page":"7660","DOI":"10.1200\/JCO.2005.02.0933","article-title":"Pegylated arginine deiminase treatment of patients with metastatic melanoma: results from phase I and II studies","volume":"23","author":"Ascierto","year":"2005","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.jtho.2018.02.021_bib138","doi-asserted-by":"crossref","first-page":"2220","DOI":"10.1200\/JCO.2009.26.7765","article-title":"Phase II study of pegylated arginine deiminase for nonresectable and metastatic hepatocellular carcinoma","volume":"28","author":"Glazer","year":"2010","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.jtho.2018.02.021_bib139","doi-asserted-by":"crossref","first-page":"954","DOI":"10.1038\/sj.bjc.6605856","article-title":"A\u00a0randomised phase II study of pegylated arginine deiminase (ADI-PEG 20) in Asian advanced hepatocellular carcinoma patients","volume":"103","author":"Yang","year":"2010","journal-title":"Br J Cancer"},{"key":"10.1016\/j.jtho.2018.02.021_bib140","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1002\/cncr.20057","article-title":"Incidence and distribution of argininosuccinate synthetase deficiency in human cancers: a method for identifying cancers sensitive to arginine deprivation","volume":"100","author":"Dillon","year":"2004","journal-title":"Cancer"},{"key":"10.1016\/j.jtho.2018.02.021_bib141","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2017.35.15_suppl.TPS8582","article-title":"ATOMIC-Meso: a randomized phase 2\/3 trial of ADI-PEG20 or placebo with pemetrexed and cisplatin in patients with argininosuccinate synthetase 1-deficient non-epithelioid mesothelioma","volume":"35","author":"Szlosarek","year":"2017","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.jtho.2018.02.021_bib142","doi-asserted-by":"crossref","DOI":"10.1093\/carcin\/bgw084","article-title":"Modeling mesothelioma utilizing human mesothelial cells reveals involvement of phospholipase-C beta 4 in YAP-active mesothelioma cell proliferation","author":"Kakiuchi","year":"2016","journal-title":"Carcinogenesis"},{"key":"10.1016\/j.jtho.2018.02.021_bib143","doi-asserted-by":"crossref","first-page":"335","DOI":"10.21037\/tlcr.2017.06.02","article-title":"Drug development against the hippo pathway in mesothelioma","volume":"6","author":"Woodard","year":"2017","journal-title":"Transl Lung Cancer Res"},{"key":"10.1016\/j.jtho.2018.02.021_bib144","doi-asserted-by":"crossref","first-page":"1693","DOI":"10.1158\/1535-7163.MCT-16-0821","article-title":"Combined inhibition of NEDD8-activating enzyme and mTOR suppresses NF2 loss-driven tumorigenesis","volume":"16","author":"Cooper","year":"2017","journal-title":"Mol Cancer Ther"},{"key":"10.1016\/j.jtho.2018.02.021_bib145","doi-asserted-by":"crossref","first-page":"7483","DOI":"10.1158\/1078-0432.CCR-17-2169","article-title":"A\u00a0randomized phase II trial of adjuvant galinpepimut-S, WT-1 analogue peptide vaccine, after multimodality therapy for patients with malignant pleural mesothelioma","volume":"23","author":"Zauderer","year":"2017","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.jtho.2018.02.021_bib146","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1158\/1078-0432.CCR-17-2522","article-title":"Autologous dendritic cells pulsed with allogeneic tumor cell lysate in mesothelioma: from mouse to human","volume":"24","author":"Aerts","year":"2018","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.jtho.2018.02.021_bib147","doi-asserted-by":"crossref","first-page":"22649","DOI":"10.18632\/oncotarget.15152","article-title":"HMGB1 targeting by ethyl pyruvate suppresses malignant phenotype of\u00a0human\u00a0mesothelioma","volume":"8","author":"Pellegrini","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.jtho.2018.02.021_bib148","doi-asserted-by":"crossref","first-page":"e1786","DOI":"10.1038\/cddis.2015.153","article-title":"Aspirin delays mesothelioma growth by inhibiting HMGB1-mediated tumor progression","volume":"6","author":"Yang","year":"2015","journal-title":"Cell Death Dis"},{"key":"10.1016\/j.jtho.2018.02.021_bib149","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1093\/neuonc\/not310","article-title":"Glioma virus therapies between bench and bedside","volume":"16","author":"Kaufmann","year":"2014","journal-title":"Neuro Oncol"},{"key":"10.1016\/j.jtho.2018.02.021_bib150","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/j.ygyno.2011.06.021","article-title":"Oncolytic virotherapy of breast cancer","volume":"123","author":"Hartkopf","year":"2011","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.jtho.2018.02.021_bib151","first-page":"1666","article-title":"[Phase III randomized clinical trial of intratumoral injection of E1B gene-deleted adenovirus (H101) combined with cisplatin-based chemotherapy in treating squamous cell cancer of head and neck or esophagus]","volume":"23","author":"Xia","year":"2004","journal-title":"Ai Zheng"},{"key":"10.1016\/j.jtho.2018.02.021_bib152","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1097\/JTO.0000000000000214","article-title":"Measles vaccine strains for virotherapy of non-small-cell lung carcinoma","volume":"9","author":"Patel","year":"2014","journal-title":"J\u00a0Thorac Oncol"},{"key":"10.1016\/j.jtho.2018.02.021_bib153","doi-asserted-by":"crossref","first-page":"2780","DOI":"10.1200\/JCO.2014.58.3377","article-title":"Talimogene laherparepvec improves durable response rate in patients with advanced melanoma","volume":"33","author":"Andtbacka","year":"2015","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.jtho.2018.02.021_bib154","doi-asserted-by":"crossref","first-page":"179","DOI":"10.3389\/fonc.2017.00179","article-title":"Oncolytic viral therapy for mesothelioma","volume":"7","author":"Pease","year":"2017","journal-title":"Front Oncol"},{"key":"10.1016\/j.jtho.2018.02.021_bib155","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1097\/00000658-199507000-00013","article-title":"Treatment of experimental human mesothelioma using adenovirus transfer of the herpes simplex thymidine kinase gene","volume":"222","author":"Smythe","year":"1995","journal-title":"Ann Surg"},{"key":"10.1016\/j.jtho.2018.02.021_bib156","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1165\/ajrcmb.13.1.7598939","article-title":"Gene therapy using adenovirus carrying the herpes simplex-thymidine kinase gene to treat in\u00a0vivo models of human malignant mesothelioma and lung cancer","volume":"13","author":"Hwang","year":"1995","journal-title":"Am J Respir Cell Mol Biol"},{"key":"10.1016\/j.jtho.2018.02.021_bib157","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1038\/sj.cgt.7700594","article-title":"Regression of AK7 malignant mesothelioma established in immunocompetent mice following intratumoral gene transfer of interferon gamma","volume":"10","author":"Cordier Kellerman","year":"2003","journal-title":"Cancer Gene Ther"},{"key":"10.1016\/j.jtho.2018.02.021_bib158","first-page":"6201","article-title":"Eradication of intraperitoneal and distant tumor by adenovirus-mediated interferon-beta gene therapy is attributable to induction of systemic immunity","volume":"61","author":"Odaka","year":"2001","journal-title":"Cancer Res"},{"key":"10.1016\/j.jtho.2018.02.021_bib159","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1002\/jgm.877","article-title":"Imaging and therapy of malignant pleural mesothelioma using replication-competent herpes simplex viruses","volume":"8","author":"Adusumilli","year":"2006","journal-title":"J\u00a0Gene Med"},{"key":"10.1016\/j.jtho.2018.02.021_bib160","doi-asserted-by":"crossref","first-page":"48","DOI":"10.4161\/cbt.5.1.2237","article-title":"Cisplatin-induced GADD34 upregulation potentiates oncolytic viral therapy in the treatment of malignant pleural mesothelioma","volume":"5","author":"Adusumilli","year":"2006","journal-title":"Cancer Biol Ther"},{"key":"10.1016\/j.jtho.2018.02.021_bib161","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1245\/s10434-006-9127-4","article-title":"Radiation-induced cellular DNA damage repair response enhances viral gene therapy efficacy in the treatment of malignant pleural mesothelioma","volume":"14","author":"Adusumilli","year":"2007","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.jtho.2018.02.021_bib162","doi-asserted-by":"crossref","DOI":"10.1093\/annonc\/mdx367.001","article-title":"366PD. Oncolytic herpesvirus therapy for mesothelioma: a phase I\/IIa trial of intrapleural administration of HSV1716 (NCT01721018)","volume":"28","author":"Danson","year":"2017","journal-title":"Ann Oncol"},{"key":"10.1016\/j.jtho.2018.02.021_bib163","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1016\/j.surg.2013.06.004","article-title":"An oncolytic vaccinia virus expressing the human sodium iodine symporter prolongs survival and facilitates SPECT\/CT imaging in an orthotopic model of malignant pleural mesothelioma","volume":"154","author":"Belin","year":"2013","journal-title":"Surgery"},{"key":"10.1016\/j.jtho.2018.02.021_bib164","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1038\/cgt.2010.10","article-title":"Oncolytic measles viruses encoding interferon beta and the thyroidal sodium iodide symporter gene for mesothelioma virotherapy","volume":"17","author":"Li","year":"2010","journal-title":"Cancer Gene Ther"},{"key":"10.1016\/j.jtho.2018.02.021_bib165","doi-asserted-by":"crossref","first-page":"44892","DOI":"10.18632\/oncotarget.6285","article-title":"Sensitivity of human pleural mesothelioma to oncolytic measles virus depends on defects of the type I interferon response","volume":"6","author":"Achard","year":"2015","journal-title":"Oncotarget"},{"key":"10.1016\/j.jtho.2018.02.021_bib166","doi-asserted-by":"crossref","first-page":"S296","DOI":"10.1016\/j.jtho.2016.11.305","article-title":"OA13.07. Intrapleural modified vaccine strain measles virus therapy for patients with malignant pleural mesothelioma","volume":"12","author":"Peikert","year":"2017","journal-title":"J\u00a0Thorac Oncol"},{"key":"10.1016\/j.jtho.2018.02.021_bib167","doi-asserted-by":"crossref","first-page":"6501","DOI":"10.1038\/onc.2017.266","article-title":"Inhibition of the spindle assembly checkpoint kinase Mps-1 as a novel therapeutic strategy in malignant mesothelioma","volume":"36","author":"Szymiczek","year":"2017","journal-title":"Oncogene"},{"key":"10.1016\/j.jtho.2018.02.021_bib168","doi-asserted-by":"crossref","first-page":"3191","DOI":"10.1158\/1078-0432.CCR-16-1971","article-title":"Co-occurring mutations of tumor suppressor genes, LATS2 and NF2, in malignant pleural mesothelioma","volume":"23","author":"Tranchant","year":"2017","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.jtho.2018.02.021_bib169","doi-asserted-by":"crossref","first-page":"45768","DOI":"10.1038\/srep45768","article-title":"HEG1 is a novel mucin-like membrane protein that serves as a diagnostic and therapeutic target for malignant mesothelioma","volume":"7","author":"Tsuji","year":"2017","journal-title":"Sci Rep"},{"key":"10.1016\/j.jtho.2018.02.021_bib170","first-page":"1724","article-title":"Targeting MYC sensitizes malignant mesothelioma cells to PAK blockage-induced cytotoxicity","volume":"7","author":"Tan","year":"2017","journal-title":"Am J Cancer Res"},{"key":"10.1016\/j.jtho.2018.02.021_bib171","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.1038\/bjc.2017.62","article-title":"First-in-human phase 1 of YS110, a monoclonal antibody directed against CD26 in advanced CD26-expressing cancers","volume":"116","author":"Angevin","year":"2017","journal-title":"Br J Cancer"},{"key":"10.1016\/j.jtho.2018.02.021_bib172","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1002\/1878-0261.12150","article-title":"A\u00a0link between the fibroblast growth factor axis and the miR-16 family reveals potential new treatment combinations in mesothelioma","volume":"12","author":"Schelch","year":"2018","journal-title":"Mol Oncol"},{"key":"10.1016\/j.jtho.2018.02.021_bib173","doi-asserted-by":"crossref","first-page":"1386","DOI":"10.1016\/S1470-2045(17)30621-6","article-title":"Safety and activity of microRNA-loaded minicells in patients with recurrent malignant pleural mesothelioma: a first-in-man, phase 1, open-label, dose-escalation study","volume":"18","author":"van Zandwijk","year":"2017","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.jtho.2018.02.021_bib174","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1016\/j.jtho.2017.10.016","article-title":"Dysregulated expression of the microRNA miR-137 and its target YB-1 contribute to the invasive characteristics of malignant pleural mesothelioma","volume":"13","author":"Johnson","year":"2018","journal-title":"J\u00a0Thorac Oncol"},{"key":"10.1016\/j.jtho.2018.02.021_bib175","doi-asserted-by":"crossref","first-page":"1421","DOI":"10.1016\/j.jtho.2017.05.024","article-title":"Tumor suppressor microRNAs contribute to the regulation of PD-L1 expression in malignant pleural mesothelioma","volume":"12","author":"Kao","year":"2017","journal-title":"J\u00a0Thorac Oncol"},{"key":"10.1016\/j.jtho.2018.02.021_bib176","doi-asserted-by":"crossref","unstructured":"Schunselaar L, Quispel-Janssen JM, Kim Y, et\u00a0al. Chemical profiling of primary mesothelioma cultures defines subtypes with different expression profiles and clinical responses [e-pub ahead of print]. Clin Cancer Res. https:\/\/doi.org\/10.1158\/1078-0432.CCR-17-1345, accessed November 30, 2017.","DOI":"10.1158\/1078-0432.CCR-17-1345"},{"key":"10.1016\/j.jtho.2018.02.021_bib177","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1158\/1078-0432.CCR-17-1172","article-title":"Comprehensive pharmacogenomic profiling of malignant pleural mesothelioma identifies a subgroup sensitive to FGFR inhibition","volume":"24","author":"Quispel-Janssen","year":"2018","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.jtho.2018.02.021_bib178","doi-asserted-by":"crossref","first-page":"1060","DOI":"10.1158\/1078-0432.CCR-16-0844","article-title":"Patient-derived xenograft establishment from human malignant pleural mesothelioma","volume":"23","author":"Wu","year":"2017","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.jtho.2018.02.021_bib179","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1016\/S1470-2045(11)70149-8","article-title":"Extra-pleural pneumonectomy versus no extra-pleural pneumonectomy for patients with malignant pleural mesothelioma: clinical outcomes of the Mesothelioma and Radical Surgery (MARS) randomised feasibility study","volume":"12","author":"Treasure","year":"2011","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.jtho.2018.02.021_bib180","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.jtcvs.2014.03.011","article-title":"Malignant pleural mesothelioma and the Society of Thoracic Surgeons Database: an analysis of surgical morbidity and mortality","volume":"148","author":"Burt","year":"2014","journal-title":"J\u00a0Thorac Cardiovasc Surg"},{"key":"10.1016\/j.jtho.2018.02.021_bib181","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1016\/j.athoracsur.2014.09.056","article-title":"Meta-analysis of survival after pleurectomy decortication versus extrapleural pneumonectomy in mesothelioma","volume":"99","author":"Taioli","year":"2015","journal-title":"Ann Thorac Surg"},{"key":"10.1016\/j.jtho.2018.02.021_bib182","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1097\/JTO.0000000000000064","article-title":"Does surgery improve survival of patients with malignant pleural mesothelioma? a multicenter retrospective analysis of 1365 consecutive patients","volume":"9","author":"Bovolato","year":"2014","journal-title":"J\u00a0Thorac Oncol"},{"key":"10.1016\/j.jtho.2018.02.021_bib183","doi-asserted-by":"crossref","first-page":"912","DOI":"10.1016\/j.athoracsur.2016.08.071","article-title":"Extended pleurectomy-decortication-based treatment for advanced stage epithelial mesothelioma yielding a median survival of nearly three years","volume":"103","author":"Friedberg","year":"2017","journal-title":"Ann Thorac Surg"},{"key":"10.1016\/j.jtho.2018.02.021_bib184","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1016\/j.jtcvs.2015.09.121","article-title":"Adoption of pleurectomy and decortication for malignant mesothelioma leads to similar survival as extrapleural pneumonectomy","volume":"151","author":"Batirel","year":"2016","journal-title":"J\u00a0Thorac Cardiovasc Surg"},{"key":"10.1016\/j.jtho.2018.02.021_bib185","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1016\/j.jtcvs.2007.10.054","article-title":"Extrapleural pneumonectomy versus pleurectomy\/decortication in the surgical management of malignant pleural mesothelioma: results in 663 patients","volume":"135","author":"Flores","year":"2008","journal-title":"J\u00a0Thorac Cardiovasc Surg"},{"key":"10.1016\/j.jtho.2018.02.021_bib186","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1016\/j.lungcan.2013.11.026","article-title":"A\u00a0systematic review and meta-analysis of surgical treatments for malignant pleural mesothelioma","volume":"83","author":"Cao","year":"2014","journal-title":"Lung Cancer"},{"key":"10.1016\/j.jtho.2018.02.021_bib187","doi-asserted-by":"crossref","first-page":"3354","DOI":"10.1200\/JCO.2017.73.8401","article-title":"Long-term survival outcomes of cancer-directed surgery for malignant pleural mesothelioma: propensity score matching analysis","volume":"35","author":"Nelson","year":"2017","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.jtho.2018.02.021_bib188","doi-asserted-by":"crossref","first-page":"1704","DOI":"10.1016\/j.jtho.2017.08.012","article-title":"National Cancer Database report on pneumonectomy versus lung-sparing surgery for malignant pleural mesothelioma","volume":"12","author":"Verma","year":"2017","journal-title":"J\u00a0Thorac Oncol"},{"key":"10.1016\/j.jtho.2018.02.021_bib189","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1093\/ejcts\/ezx079","article-title":"Pleurectomy-decortication in malignant pleural mesothelioma: are different surgical techniques associated with different outcomes? Results from a multicentre study","volume":"52","author":"Marulli","year":"2017","journal-title":"Eur J Cardiothorac Surg"},{"key":"10.1016\/j.jtho.2018.02.021_bib190","doi-asserted-by":"crossref","first-page":"230","DOI":"10.21037\/atm.2017.03.41","article-title":"The impact of surgical approach on quality of life for pleural malignant mesothelioma","volume":"5","author":"Schwartz","year":"2017","journal-title":"Ann Transl Med"},{"key":"10.1016\/j.jtho.2018.02.021_bib191","doi-asserted-by":"crossref","first-page":"S1748","DOI":"10.1016\/j.jtho.2017.09.333","article-title":"OA 02.07. Surgical selection in pleurectomy decortication for mesothelioma\u2014an overview from screening and selection from MARS 2 Pilot","volume":"12","author":"Trialists","year":"2017","journal-title":"J\u00a0Thorac Oncol"},{"key":"10.1016\/j.jtho.2018.02.021_bib192","doi-asserted-by":"crossref","first-page":"1516","DOI":"10.1093\/ejcts\/ezv398","article-title":"Relapse pattern and second-line treatment following multimodality treatment for malignant pleural mesothelioma","volume":"49","author":"Kostron","year":"2016","journal-title":"Eur J Cardiothorac Surg"},{"key":"10.1016\/j.jtho.2018.02.021_bib193","doi-asserted-by":"crossref","first-page":"1651","DOI":"10.1016\/S1470-2045(15)00208-9","article-title":"Neoadjuvant chemotherapy and extrapleural pneumonectomy of malignant pleural mesothelioma with or without hemithoracic radiotherapy (SAKK 17\/04): a randomised, international, multicentre phase 2 trial","volume":"16","author":"Stahel","year":"2015","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.jtho.2018.02.021_bib194","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.radonc.2017.08.003","article-title":"The role of radical radiotherapy in the management of malignant pleural mesothelioma: a systematic review","volume":"125","author":"Ashton","year":"2017","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.jtho.2018.02.021_bib195","doi-asserted-by":"crossref","first-page":"1278","DOI":"10.1016\/j.ijrobp.2011.09.027","article-title":"Pleural intensity-modulated radiotherapy for malignant pleural mesothelioma","volume":"83","author":"Rosenzweig","year":"2012","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.jtho.2018.02.021_bib196","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1016\/j.ijrobp.2014.05.032","article-title":"Failure patterns after hemithoracic pleural intensity modulated radiation therapy for malignant pleural mesothelioma","volume":"90","author":"Rimner","year":"2014","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.jtho.2018.02.021_bib197","doi-asserted-by":"crossref","first-page":"2761","DOI":"10.1200\/JCO.2016.67.2675","article-title":"Phase II study of hemithoracic intensity-modulated pleural radiation therapy (IMPRINT) as part of lung-sparing multimodality therapy in patients with malignant pleural mesothelioma","volume":"34","author":"Rimner","year":"2016","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.jtho.2018.02.021_bib198","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1016\/j.jtho.2017.02.026","article-title":"Improved outcomes with modern lung-sparing trimodality therapy in patients with malignant pleural mesothelioma","volume":"12","author":"Shaikh","year":"2017","journal-title":"J\u00a0Thorac Oncol"},{"key":"10.1016\/j.jtho.2018.02.021_bib199","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1016\/j.jtcvs.2015.09.129","article-title":"Accelerated hemithoracic radiation followed by extrapleural pneumonectomy for malignant pleural mesothelioma","volume":"151","author":"de Perrot","year":"2016","journal-title":"J\u00a0Thorac Cardiovasc Surg"},{"key":"10.1016\/j.jtho.2018.02.021_bib200","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1093\/ejcts\/ezw074","article-title":"Impact of induction therapy on postoperative outcome after extrapleural pneumonectomy for malignant pleural mesothelioma: does induction-accelerated hemithoracic radiation increase the surgical risk?","volume":"50","author":"Mordant","year":"2016","journal-title":"Eur J Cardiothorac Surg"},{"key":"10.1016\/j.jtho.2018.02.021_bib201","doi-asserted-by":"crossref","first-page":"S1747","DOI":"10.1016\/j.jtho.2017.09.331","article-title":"OA 02.05. RESPECT-MESO: an international randomized controlled trial to assess early specialist palliative care in malignant pleural mesothelioma","volume":"12","author":"Brims","year":"2017","journal-title":"J\u00a0Thorac Oncol"},{"key":"10.1016\/j.jtho.2018.02.021_bib202","doi-asserted-by":"crossref","first-page":"S1747","DOI":"10.1016\/j.jtho.2017.09.330","article-title":"OA 02.03. Prophylactic irradiation of tracts (PIT) in patients with pleural mesothelioma: results of a multicenter phase III trial","volume":"12","author":"Bayman","year":"2017","journal-title":"J\u00a0Thorac Oncol"},{"key":"10.1016\/j.jtho.2018.02.021_bib203","doi-asserted-by":"crossref","first-page":"1903","DOI":"10.1001\/jama.2017.17426","article-title":"Effect of an indwelling pleural catheter vs talc pleurodesis on hospitalization days in patients with malignant pleural effusion: the AMPLE randomized clinical trial","volume":"318","author":"Thomas","year":"2017","journal-title":"JAMA"},{"key":"10.1016\/j.jtho.2018.02.021_bib204","first-page":"638","article-title":"Subcutaneous tumor growth complicating the positioning of Denver shunt and intrapleural port-a-cath in mesothelioma patients","volume":"18","author":"van Ooijen","year":"1992","journal-title":"Eur J Surg Oncol"}],"container-title":["Journal of Thoracic Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1556086418301758?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1556086418301758?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T10:37:48Z","timestamp":1761561468000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1556086418301758"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,5]]},"references-count":204,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2018,5]]}},"alternative-id":["S1556086418301758"],"URL":"https:\/\/doi.org\/10.1016\/j.jtho.2018.02.021","relation":{},"ISSN":["1556-0864"],"issn-type":[{"value":"1556-0864","type":"print"}],"subject":[],"published":{"date-parts":[[2018,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Progress in the Management of Malignant Pleural\u00a0Mesothelioma in 2017","name":"articletitle","label":"Article Title"},{"value":"Journal of Thoracic Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jtho.2018.02.021","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 International Association for the Study of Lung Cancer. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}